PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.12632 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589721619922944 |
|---|---|
| author | Abul Azad Maryam Arshad Daniele Generali Katharina Feldinger Merel Gijsen Carla Strina Mariarosa Cappelletti Daniele Andreis Russell Leek Syed Haider Pirkko‐Liisa Kellokumpu‐Lehtinen Ioannis Roxanis Adrian Llewellyn Harris Abeer Mahmoud Shaaban Heikki Joensuu Anthony Kong |
| author_facet | Abul Azad Maryam Arshad Daniele Generali Katharina Feldinger Merel Gijsen Carla Strina Mariarosa Cappelletti Daniele Andreis Russell Leek Syed Haider Pirkko‐Liisa Kellokumpu‐Lehtinen Ioannis Roxanis Adrian Llewellyn Harris Abeer Mahmoud Shaaban Heikki Joensuu Anthony Kong |
| author_sort | Abul Azad |
| collection | DOAJ |
| format | Article |
| id | doaj-art-ae3fd92c7a4645f2a36aa6dc4a9dc4e9 |
| institution | Kabale University |
| issn | 2523-3548 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Communications |
| spelling | doaj-art-ae3fd92c7a4645f2a36aa6dc4a9dc4e92025-01-24T09:09:48ZengWileyCancer Communications2523-35482025-01-01451687310.1002/cac2.12632PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancerAbul Azad0Maryam Arshad1Daniele Generali2Katharina Feldinger3Merel Gijsen4Carla Strina5Mariarosa Cappelletti6Daniele Andreis7Russell Leek8Syed Haider9Pirkko‐Liisa Kellokumpu‐Lehtinen10Ioannis Roxanis11Adrian Llewellyn Harris12Abeer Mahmoud Shaaban13Heikki Joensuu14Anthony Kong15Department of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKInstitute of Genomic and Cancer Sciences Vincent Drive, University of Birmingham Birmingham UKU.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona ItalyDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKU.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona ItalyU.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona ItalyU.O. Multidisciplinare di Patologia Mammaria U.S Terapia Molecolare e Farmacogenomica A.O. Instituti Ospitalieri di Cremona Viale Concordia 1 Cremona ItalyDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKDepartment of Oncology Tampere University Hospital and Tampere University Tampere FinlandThe Institute of Cancer Research London UKDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKDepartment of histopathology Queen Elizabeth Hospital Birmingham Birmingham UKDepartment of Oncology Helsinki University Hospital and University of Helsinki Helsinki FinlandDepartment of Oncology The Weatherall Institute of Molecular Medicine University of Oxford Oxford UKhttps://doi.org/10.1002/cac2.12632 |
| spellingShingle | Abul Azad Maryam Arshad Daniele Generali Katharina Feldinger Merel Gijsen Carla Strina Mariarosa Cappelletti Daniele Andreis Russell Leek Syed Haider Pirkko‐Liisa Kellokumpu‐Lehtinen Ioannis Roxanis Adrian Llewellyn Harris Abeer Mahmoud Shaaban Heikki Joensuu Anthony Kong PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer Cancer Communications |
| title | PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer |
| title_full | PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer |
| title_fullStr | PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer |
| title_full_unstemmed | PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer |
| title_short | PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer |
| title_sort | ptpn9 regulates her3 phosphorylation during trastuzumab treatment and loss of ptpn9 is a potential biomarker for trastuzumab resistance in her2 positive breast cancer |
| url | https://doi.org/10.1002/cac2.12632 |
| work_keys_str_mv | AT abulazad ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT maryamarshad ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT danielegenerali ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT katharinafeldinger ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT merelgijsen ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT carlastrina ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT mariarosacappelletti ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT danieleandreis ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT russellleek ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT syedhaider ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT pirkkoliisakellokumpulehtinen ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT ioannisroxanis ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT adrianllewellynharris ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT abeermahmoudshaaban ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT heikkijoensuu ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer AT anthonykong ptpn9regulatesher3phosphorylationduringtrastuzumabtreatmentandlossofptpn9isapotentialbiomarkerfortrastuzumabresistanceinher2positivebreastcancer |